respiratori
syncyti
viru
rsv
signific
caus
bronchiol
pneumonia
sever
high
health
risk
popul
includ
infant
elderli
immunocompromis
individu
mortal
hematopoiet
stem
cell
transplant
recipi
lower
respiratori
tract
rsv
infect
exceed
shown
rsv
replic
immunosuppress
individu
significantli
prolong
contribut
pulmonari
damag
pathogenesi
rsv
diseas
suscept
popul
known
work
test
novel
standard
ig
formul
contain
high
level
rsvneutral
ab
abil
control
rsv
infect
immunocompromis
cotton
rat
sigmodon
hispidu
anim
immunosuppress
repeat
cyclophosphamid
inject
infect
rsv
treat
prolong
rsv
replic
characterist
immunosuppress
cotton
rat
inhibit
administr
ab
treatment
reduc
detect
system
dissemin
viral
rna
importantli
pulmonari
interstiti
inflamm
epitheli
hyperplasia
significantli
elev
immunosuppress
anim
reduc
administr
result
indic
potenti
improv
outcom
rsv
infect
immunocompromis
subject
control
viral
replic
also
reduc
damag
lung
parenchyma
epitheli
airway
line
studi
need
respiratori
syncyti
viru
rsv
signific
caus
bronchiol
pneumonia
highrisk
infant
children
elderli
immunocompromis
individu
among
hematopoiet
stem
cell
transplant
recipi
hsct
rsv
affect
patient
infect
progress
lower
respiratori
tract
infect
case
mortal
rate
rsv
lower
respiratori
tract
infect
hsct
patient
left
untreat
reach
higher
studi
patient
hematolog
disord
recipi
hsct
show
maintain
dramat
prolong
rsv
replic
report
median
durat
day
earli
intervent
ribavirin
aerosol
oral
reduc
mortal
associ
rsv
infect
patient
hematolog
malign
transplant
recipi
highlight
import
control
viral
replic
cohort
howev
significantli
higher
dose
ribavirin
requir
achiev
therapeut
effect
efficaci
ribavirin
therapi
may
improv
combin
administr
intraven
immunoglobulin
ivig
intraven
rsv
immunoglobulin
rsvivig
prepar
contain
time
amount
rsvneutral
ab
found
standard
ivig
prepar
rsvivig
respigam
approv
prophylaxi
rsv
infect
longer
manufactur
http
wwwaetnacomcpbmedicaldata
human
monoclon
ab
palivizumab
current
avail
drug
prevent
rsv
highrisk
infant
children
palivizumab
use
adult
patient
restrict
due
cost
consider
nevertheless
test
hsct
patient
part
combin
therapi
ribavirin
treatment
found
safe
welltoler
howev
efficaci
conclus
normal
immunocompet
subject
antivir
administ
rsv
infect
reduc
viral
replic
amelior
diseas
contrast
antivir
given
infect
reduc
viral
replic
diseas
suggest
trigger
inflammatori
respons
lead
cytokin
respons
subsequ
pulmonari
patholog
remain
even
viral
load
decreas
cellular
infiltr
lung
larg
compon
rsvinduc
pulmonari
damag
shown
use
anim
model
combin
antivir
exampl
palivizumab
antiinflammatori
exampl
corticosteroid
treatment
may
repres
effect
therapeut
regim
howev
whether
approach
would
requir
immunosuppress
individu
known
pulmonari
patholog
hsct
patient
rsv
infect
may
mediat
lung
damag
caus
prolong
viral
replic
case
treatment
drug
strong
antivir
activ
may
higher
therapeut
efficaci
immunosuppress
patient
compar
immunocompet
individu
infect
rsv
reduct
pulmonari
damag
caus
excess
viral
replic
work
test
novel
rsvivig
formul
manufactur
complianc
food
drug
administr
standard
treat
patient
immun
defici
diseas
abil
reduc
rsv
infect
normal
immunocompromis
cotton
rat
hispidu
cotton
rat
model
accur
reproduc
significantli
prolong
rsv
replic
condit
immunosuppress
cotton
rat
instrument
prove
efficaci
ab
immunoprohylaxi
led
develop
respigam
palivizumab
model
also
confirm
antirsv
ab
less
effect
given
onset
rsv
infect
indic
import
contribut
host
inflammatori
respons
infect
pathogenesi
rsv
diseas
goal
particular
work
determin
whether
mitig
prolong
rsv
replic
reduc
patholog
rsv
diseas
immunosuppress
cotton
rat
intraven
immun
globulin
human
human
igg
prepar
contain
standard
amount
rsvneutral
antibodi
isol
sourc
plasma
obtain
donor
select
high
titer
natur
occur
neutral
ab
rsv
refer
ab
respigam
liquid
sd
lot
refer
rsvivig
cyclophosphamid
cy
inject
mgml
usp
baxter
deerfield
il
usa
obtain
adma
biolog
ramsey
nj
usa
blue
door
pharma
rockvil
md
usa
respect
prototyp
along
strain
rsv
obtain
american
type
cultur
collect
manassa
va
usa
viru
propag
cell
serial
plaquepurifi
reduc
defectiveinterf
particl
singl
pool
rsv
along
plaqueform
unit
pfu
ml
use
studi
describ
herein
rsv
viral
titer
lung
infect
anim
determin
plaqu
assay
anim
anim
studi
inbr
hispidu
cotton
rat
obtain
coloni
maintain
sigmovir
biosystem
inc
sixto
eightweekold
inbr
femal
cotton
rat
use
studi
without
need
addit
random
anim
hous
larg
polycarbon
cage
fed
standard
diet
rodent
chow
water
coloni
monitor
ab
adventiti
respiratori
virus
common
rodent
pathogen
ab
found
studi
conduct
applic
law
guidelin
approv
institut
anim
care
use
committe
sigmovir
biosystem
inc
efficaci
therapi
prophylaxi
verifi
two
consecut
experi
conduct
first
normal
immunosuppress
anim
sampl
size
five
anim
per
group
chosen
base
result
previou
experi
allow
detect
statist
signific
differ
group
comparison
group
run
use
student
ttest
unpair
data
unequ
varianc
kaleidagraph
synergi
softwar
read
pa
usa
unless
indic
sampl
blind
analysi
studi
prophylaxi
normal
cotton
rat
anim
inocul
ip
isofluran
anesthesia
h
later
challeng
rsv
along
pfu
per
anim
administ
intranas
control
anim
inocul
ip
salin
respigam
solut
h
rsv
infect
anim
kill
co
asphyxi
day
post
infect
lung
nose
sampl
collect
viral
quantif
plaqu
assay
blood
collect
infect
kill
anim
quantif
rsvneutral
ab
via
microneutr
assay
studi
therapi
rsv
infect
anim
treat
h
rsv
infect
kill
day
post
infect
control
anim
inocul
ip
salin
immunosuppress
induc
cotton
rat
repeat
treatment
cy
base
method
describ
modif
cy
dose
mgkg
administ
im
therapi
studi
ip
prophylaxi
studi
isofluran
anesthesia
per
g
anim
day
end
period
whole
blood
serum
sampl
collect
verifi
declin
total
white
blood
cell
lymphocyt
count
cy
treatment
continu
end
studi
twentyon
day
start
cy
treatment
anim
infect
rsv
along
pfu
per
anim
day
post
infect
anim
treat
ip
control
immunosuppress
rsvinfect
anim
inocul
ip
salin
intern
control
rsv
infect
without
immunosuppress
agematch
normal
anim
infect
rsv
treat
salin
ip
day
post
infect
group
five
anim
kill
day
post
infect
collect
lung
nose
viral
quantif
plaqu
assay
day
post
infect
lung
collect
histopatholog
analysi
fragment
liver
kidney
snapfrozen
quantit
pcr
analysi
blood
sampl
collect
anim
anim
kill
wbc
lymphocyt
count
analys
microneutr
assay
prophylaxi
studi
immunosuppress
cotton
rat
given
ip
one
day
infect
rsv
follow
treatment
day
post
infect
sampl
collect
analysi
viral
replic
day
post
infect
lung
prepar
histopatholog
analysi
previous
describ
score
blindli
peribronchiol
inflammatori
cell
around
small
airway
perivascul
inflammatori
cell
around
small
blood
vessel
alveol
inflammatori
cell
within
alveolar
space
interstiti
pneumon
inflammatori
cell
infiltr
thicken
alveolar
wall
paramet
score
scale
epitheli
damag
evalu
hyperplasia
airway
epitheli
cell
line
multilay
cell
arrang
small
papillaelik
structur
project
airway
lumen
score
scale
absent
minim
mild
moder
express
rsv
mrna
analyz
rna
extract
differ
organ
realtim
quantit
sybr
green
pcr
previous
describ
neutral
ab
assay
antirsvneutr
titer
cotton
rat
serum
sampl
determin
microneutr
assay
previous
describ
brief
serum
dilut
incub
pfu
rsv
strain
min
room
temperatur
follow
addit
cell
cultur
plate
day
quantiti
rsv
ag
determin
rsv
enzym
immunoassay
use
monoclon
ab
rsv
f
protein
neutral
titer
defin
serum
dilut
result
reduct
color
develop
verifi
antivir
potenc
prophylaxi
normal
cotton
rat
inocul
ip
mgkg
infect
pfu
rsv
along
per
anim
h
later
lung
nose
harvest
viral
titrat
day
infect
viral
load
rsvinfect
anim
compar
rsvinfect
anim
treat
salin
inocul
posit
control
refer
rsvivig
formul
respigam
mgkg
salinetr
rsvinfect
anim
log
pfug
rsv
lung
nose
tissu
respect
figur
complet
protect
lung
rsv
replic
dose
test
signific
reduct
viral
replic
nose
also
achiev
lung
protect
afford
improv
compar
induc
refer
respigam
formul
level
rsvneutral
ab
quantifi
microneutr
assay
serum
collect
immedi
infect
time
anim
kill
tabl
data
show
doserespons
serum
rsvneutral
titer
correl
protect
evidenc
lung
nose
rsv
viral
titer
cotton
rat
tissu
determin
abil
reduc
rsv
load
administ
infect
therapi
anim
infect
rsv
treat
one
day
later
treatment
mgkg
complet
suppress
viral
load
lung
infect
anim
day
post
infect
figur
treatment
mgkg
abolish
replic
rsv
lung
two
five
anim
bare
detect
viru
isol
remain
three
anim
group
rsv
replic
nose
also
reduc
anim
dosedepend
manner
efficaci
rsv
infect
immunosuppress
cotton
rat
cotton
rat
immunosuppress
via
repeat
cyclophosphamid
treatment
administ
period
figur
blood
sampl
collect
anim
kill
use
verifi
drop
white
blood
cell
wbc
lymphocyt
count
immunosuppress
cotton
rat
rise
serum
rsvneutral
ab
titer
anim
figur
significantli
delay
viral
clearanc
seen
immunosuppress
cotton
rat
infect
rsv
figur
although
normal
cotton
rat
treat
salin
clear
rsv
day
post
infect
immunosuppress
salinetr
anim
log
pfu
viru
lung
nose
time
immunosuppress
cotton
rat
inocul
rsv
challeng
reduct
viral
load
lung
nose
day
post
infect
compar
salinetr
immunosuppress
cotton
rat
hll
hhh
regim
treatment
effect
suppress
viral
replic
determin
whether
effect
pulmonari
patholog
associ
prolong
rsv
replic
immunosuppress
anim
lung
tissu
collect
histopatholog
analysi
day
post
infect
immunosuppress
anim
sever
inflamm
lung
parenchyma
interstiti
pneumonia
nonimmunosuppress
anim
figur
b
immunosuppress
rsv
infect
also
associ
signific
hyperplasia
mucos
epithelium
conduct
airway
absent
nonimmunosuppress
rsvinfect
anim
figur
b
compar
top
bottom
panel
immunosuppress
rsvinfect
anim
treat
highdos
antivir
regim
littl
inflamm
parenchyma
significantli
reduc
epitheli
hyperplasia
figur
compar
top
middl
panel
wherea
intermediatedos
treatment
slightli
less
effect
reduc
epitheli
damag
result
suggest
highdos
antivir
regimen
reduc
pneumonia
airway
epitheli
hyperplasia
immunosuppress
anim
infect
rsv
hyperplasia
like
respons
airway
epitheli
injuri
find
suggest
highdos
antivir
regim
may
either
protect
anim
past
ongo
bronchiolar
injuri
may
enhanc
recoveri
airway
epithelium
immunosuppress
anim
viral
infect
rsv
gene
express
organ
outsid
respiratori
tract
evalu
immunosuppress
cotton
rat
infect
rsv
sampl
liver
kidney
collect
day
post
infect
analyz
realtim
pcr
liver
kidney
immunosuppress
rsvinfect
anim
treat
salin
elev
express
rsv
gene
compar
liver
kidney
sampl
normal
anim
infect
rsv
treat
salin
figur
although
differ
fail
reach
statist
signific
treatment
immunosuppress
rsvinfect
anim
appear
reduc
rsv
express
liver
kidney
basal
level
detect
normal
cotton
rat
infect
rsv
ivig
also
use
evalu
prophylact
efficaci
rsvivig
rsv
diseas
immunosuppress
anim
cotton
rat
immunosuppress
cy
treat
one
day
rsv
infect
day
post
rsv
infect
total
three
repeat
dose
mgkg
mgkg
lung
immunosuppress
anim
treat
mgkg
complet
protect
rsv
replic
day
post
infect
figur
anim
treat
mgkg
rsvig
detect
viral
replic
lung
day
post
infect
minim
detect
replic
two
five
anim
group
plaqu
record
day
sampl
studi
describ
demonstr
treatment
significantli
improv
outcom
rsv
diseas
immunocompromis
cotton
rat
treatment
found
acceler
viral
clearanc
reduc
damag
pulmonari
tissu
airway
result
repres
mean
se
anim
per
group
p
compar
rsvinfect
immunosuppress
anim
treat
salin
kill
day
line
repeat
administr
use
achiev
desir
effect
base
earlier
observ
insuffici
number
treatment
lead
rebound
rsv
replic
immunosuppress
anim
undergo
ab
therapi
regim
consist
three
administr
mgkg
larg
compar
antivir
efficaci
combin
treatment
includ
one
dose
mgkg
follow
two
dose
mgkg
howev
highdos
treatment
repeat
mg
kg
dose
appear
effect
restor
pulmonari
histolog
level
similar
seen
normal
cotton
rat
infect
rsv
normal
cotton
rat
singl
administr
mgkg
given
prophylact
inhibit
rsv
replic
lower
respiratori
tract
reduc
viral
titer
undetect
level
stronger
antivir
effect
correl
higher
serum
rsvneutral
ab
titer
achiev
one
day
ab
inocul
consist
previous
establish
correl
serum
rsvneutral
ab
titer
rsv
load
infus
amelior
pulmonari
patholog
associ
prolong
rsv
replic
immunosuppress
cotton
rat
elev
interstiti
pneumonia
epitheli
hyperplasia
featur
characterist
immunosuppress
rsvinfect
anim
strongli
reduc
antivir
therapi
therefor
appear
effect
standalon
treatment
pulmonari
diseas
immunosuppress
compar
normal
cotton
rat
infect
rsv
suggest
excess
viral
replic
may
inde
drive
factor
rsv
pathogenesi
immunosuppress
subject
rsv
antivir
may
higher
therapeut
potenti
standalon
treatment
immunosuppress
patient
futur
studi
human
patient
popul
need
confirm
hypothesi
addit
antivir
activ
antiinflammatori
activ
present
ivig
could
benefici
could
contribut
diseaseamelior
effect
seen
work
dissemin
microbi
pathogen
outsid
primari
target
organ
also
signific
problem
bone
marrow
transplant
recipi
dissemin
rsv
immunocompromis
patient
well
document
rsv
rna
detect
blood
found
correl
poor
outcom
rsv
lower
respiratori
tract
diseas
hsct
recipi
result
show
detect
rsv
rna
outsid
respiratori
tract
immunosuppress
cotton
rat
reduc
treatment
welldefin
segment
patient
immun
defici
diseas
requir
regular
infus
ig
reconstitut
defici
humor
ab
compart
also
extrem
suscept
rsv
diseas
withdraw
respigam
market
import
ivig
product
arsen
control
rsv
diseas
vulner
popul
longer
avail
improv
efficaci
ivig
vs
palivizumab
rsv
hsct
patient
suggest
broader
spectrum
ab
may
requir
pivot
phase
iii
clinic
trial
patient
immun
defici
diseas
recent
complet
favor
secondari
outcom
achiev
suggest
uniqu
ab
profil
may
contribut
posit
result
higher
titer
ab
rsv
also
contain
significantli
higher
titer
ab
respiratori
virus
includ
coronaviru
parainfluenza
viru
metapneumoviru
influenza
viru
manuscript
submit
public
multipl
respiratori
virus
includ
adenovirus
rhinovirus
coronavirus
higher
infect
rate
hsct
recipi
may
prolong
viral
replic
subject
lower
respiratori
tract
infect
complic
rate
high
rsv
influenza
parainfluenza
adenovirus
human
metapneumoviru
review
shah
et
al
suggest
polyval
broad
antivir
characterist
ivig
may
import
patient
popul
figur
effect
prophylaxi
rsv
replic
immunosuppress
cotton
rat
cotton
rat
immunosuppress
cyclophosphamid
inocul
low
dose
mgkg
high
dose
twentyfour
hour
later
anim
infect
pfu
rsv
along
per
anim
day
post
infect
treatment
repeat
dose
origin
one
group
anim
kill
day
post
infect
lung
collect
viral
titrat
vt
control
anim
immunosuppress
infect
rsv
inocul
salin
one
day
day
post
infect
result
repres
mean
se
anim
per
group
compar
rsvinfect
anim
treat
salin
kill
day
